FDA issues recalls on at least 16 food and drug items in September. Here's a list
The FDA has removed the following items from store shelves this September, including pet food, baby powder and Lactaid.
FDA’s proposed packaged food labels won’t fix our obesity epidemic
A clear FDA public education campaign could help shoppers make healthier choices. But it should first pay attention to the ...
FierceBiotech1h
With post hoc analysis, BridgeBio touts case for acoramidis as FDA decision date draws near
BridgeBio Pharma has been on the road to redemption ever since its treatment for a rare and fatal heart condition, acoramidis ...
The Washington Post on MSN3d
FDA approves a novel drug for schizophrenia, a potential ‘game changer’
“This drug takes the first new approach to schizophrenia treatment in decades,” Tiffany Farchione, director of FDA’s ...
The FDA Is Launching New Traceability Rules for Added Food Safety — and Everyone Is Confused
On January 20, 2026, the Food and Drug Administration's (FDA) new traceability rules — dubbed the Food Traceability Final ...
Severity of various FDA product recalls including Class I which can cause death, serious illness
Hundreds of foods are recalled by the FDA every year. Food recalls could fall into different categories, depending on how ...
Accelerate Diagnostics Announces FDA Clearance of its Accelerate Arc(TM) System
Accelerate Diagnostics, Inc. (NASDAQ: AXDX), an innovator of rapid in vitro diagnostics, announced that the U.S. Food and Drug Administration (FDA) has granted 510(k) clearance of the Accelerate Arc ...
Biotech Stocks Facing FDA Decision In October 2024
September saw several notable 'firsts' in the regulatory landscape alongside the approval of four novel drugs in the U.S. Among ...
NBC New York4d
FDA issues recall notices over 2 brands of pet food due to salmonella and listeria risk
Amid an ongoing pet food recall, the U.S. Food and Drug Administration (FDA) is urging pet owners not to give their dogs ...
FDA proposes reclassifying hepatitis B assays
The FDA plans to move the assays from higher-risk class III devices to class II, making them eligible for the 510(k) pathway.